Menu
© 2019 All rights reserved.
TMC Life Sciences Berhad Co. No.: 200301021989 (624409-A)
Aged 48, Malaysian
Dato’ Dr. Adzuan Abdul Rahman joined TMC Life Sciences Berhad as Group Chief Executive Officer on 10 February 2025. He is also currently the Regional Senior Director of Thomson Medical Group.
Dato’ Dr. Adzuan is a seasoned healthcare leader and entrepreneur with over 20 years of experience in clinical practice, hospital management, and corporate strategy. His career spans leadership roles across Malaysia, Singapore, Hong Kong, and the broader Southeast Asia region, driving innovation, operational excellence, and business growth in the healthcare sector.
Trained as a doctor in the United Kingdom, Dato’ Dr. Adzuan began his career in medical practice before expanding into corporate healthcare after earning an MBA from IMD Business School, Switzerland. He has since held key executive roles at Parkway Laboratories, Gleneagles Hospital Kuala Lumpur, and Parkway East Hospital, where he spearheaded operational improvements, patient care enhancements, and strong financial performance.
At idsMED Group, he served as Regional Managing Director and Executive Vice President, leading the company’s strategic expansion and business optimisation. Most recently, he co-founded Novotec Pte Ltd, integrating Generative AI and innovative technologies into healthcare.
He holds a Bachelor of Medicine, Surgery, and Obstetrics from Queen’s University Belfast and has completed executive education in Mergers & Acquisitions at Imperial College Business School, UK.
Dato’ Dr. Adzuan does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.
Aged 51, Malaysian
Mr. Wong Yu Chee brings over 28 years of extensive experience in finance, audit, accounting, and tax compliance services in Malaysia and Shanghai.
Mr. Wong began his career in 1996 as an auditor at a local audit firm. In 1997, he joined Coopers & Lybrand, now known as PricewaterhouseCoopers PLT. (“Pwc”), where he spent eight years specialising in assurance assignments for large
multinational companies, public listed companies across various industries, Initial Public Offerings (“IPO”), and corporate exercises.
Following his tenure at PwC, Mr. Wong served as a Finance Manager at GlaxoSmithKline before relocating to Shanghai in late 2005 to join Ernst & Young. During his three-year tenure at Ernst & Young Shanghai, he focused on statutory audit assignments, IPO assurance assignments, corporate exercises, and United States audit assignments. Subsequently, Mr. Wong joined TMF Shanghai, where he led accounting and tax compliance services for two years.
In 2010, Mr. Wong returned to Malaysia as the Director of Accounting & Tax Compliance Services at TMF Malaysia, providing assistance to businesses in accounting and tax compliance, including Goods and Services Tax advisory services. In 2015, he joined PCA Corporate Services Sdn. Bhd. as the Group Chief Operating Officer before joining the Company as Group Chief Financial Officer on 3 August 2015.
Mr. Wong holds the designation of Fellow Member of the Association of Chartered Certified Accountants (FCCA), member of the Malaysian Institute of Accountants (MIA) – Chartered Accountant (M), and Associate Member of the Chartered Tax Institute of Malaysia (ACTIM).
Mr. Wong does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.
Aged 60, Malaysian
Ms. Lakshmi Menon joined the team as the Chief Executive Officer of TMC Fertility Holdings Sdn. Bhd. in January 2024.
Ms. Lakshmi brings extensive operational and commercial experience to TMC Fertility with over 25 years of experience in the healthcare and fertility industry in Malaysia. She
has held senior management roles in healthcare organisations like Subang Jaya Medical Centre, Damansara Fertility Centre and the Qualitas Medical Group. Ms. Lakshmi has a strong track record of improving business performance and accelerating growth. Prior to joining TMC Life Sciences Berhad, Ms. Lakshmi was attached with Sunfert International Fertility Group as the General Manager where she led cross-discipline teams across the group consisting of six fertility clinics in delivering patient-centric quality fertility care through commitment for excellence in patient experience and innovative practices.
Ms. Lakshmi holds a Master’s in Business Administration from Southern Cross University, Australia and a Bachelor of Science, Nutrition & Dietetics from University of Madras, India.
Ms. Lakshmi does not hold any directorship in other public companies and listed issuer in Malaysia. She has no family relationships with any Director and/or major shareholders of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, she has no conflicts of interest with the Company.
Aged 47, Malaysian
Dr. Siva Kumaran Jayaraman joined Thomson Hospitals Sdn. Bhd. as Chief Operating Officer (Clinical) in December 2022. He is currently the Acting Chief Executive Officer and Chief Operating Officer (COO) of Thomson Hospitals Sdn. Bhd.
He possessed over a decade of clinical experience in the government sector. Prior to joining Thomson Hospitals Sdn. Bhd., Dr. Siva Kumaran has held senior management positions at two large public hospitals. During his tenure at Hospital Selayang, he established a new medico-legal unit and in his capacity as Deputy Director (Surgical Services) at Hospital Selayang, he oversaw the enhancement of surgical disciplines and patient care.
In February 2022, Dr. Siva Kumaran became Deputy Director 1 at Hospital Serdang, managing a 1,000-bed hospital with 34 specialties. His role encompassed managing clinical services, new projects, regulatory compliance, and ensuring high standards of patient care. His leadership, critical thinking, and problem-solving skills were crucial in maintaining smooth hospital operations in high-pressure environments.
Since joining Thomson Hospitals Sdn. Bhd., Dr. Siva Kumaran has pursued strategic and efficient improvement of the hospital’s operation and clinical services. His experience in managing large tertiary hospitals has been key to driving Thomson Hospitals Sdn. Bhd.’s strategic objectives and enhancing patient care quality.
As Acting CEO and COO, Dr. Siva Kumaran is committed to Thomson Hospitals Sdn. Bhd.’s mission of helping people live healthier lives by providing accessible, accountable, and sustainable healthcare. He aims to foster continuous improvement and innovation, expand services, integrate advanced medical technologies, and ensure Thomson Hospitals Sdn. Bhd., remains a leader in healthcare delivery in Malaysia.
He holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Manipal Academy of Higher Education, India (2005) and a Master’s in Healthcare Administration from Flinders University of South Australia (2018).
Dr. Siva Kumaran does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.